IP Library Granted Patent US 8,993,343
Granted Patent B2
US 8,993,343 · App. 13/146,876 · Granted Mar 31, 2015

CD93 or use of soluble fragment thereof

Inventors: Young Woo Park (Daejon, KR); Jae Won Jeon (Daejeon, KR); Joon-Goo Jung (Daejeon, KR); Hye In Choi (Daejeon, KR); Myung-ho Sohn (Daejeon, KR); Ho youn Kim (Seoul, KR); Mi-La Cho (Seoul, KR); Young-Soon Jang (Daejeon, KR); Ji-Hun Moon (Daejeon, KR); Ji Hyun Park (Gyeongsangnam-do, KR)
Assignee: Korea Research Institute of Bioscience and Biotechnology
A61K31/7105G01N33/6893G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,993,343
App. No.
13/146,876
Granted
Mar 31, 2015
Kind
B2
Abstract

The present invention relates to an anti-inflammatory composition using the antibody specifically binding to CD93 or its soluble fragment, and a diagnostic method and a diagnostic kit for inflammatory disease using CD93 or its soluble fragment specific antibody or aptamer.

Claims (12)

1. A method for diagnosing rheumatoid arthritis comprising:

coating proteins from a biological sample obtained from synovial fluid and a control on a fixture;

inducing an antigen-antibody reaction by adding an antibody specifically binding to a CD93 soluble fragment to the above fixture;

detecting the antigen-antibody reaction product produced by the above antigen-antibody reaction by using a secondary antibody conjugate marker and chromogenic substrate solution;

comparing the detection results between the biological sample and the control; and

diagnosing rheumatoid arthritis or high risk of rheumatoid arthritis when CD93 soluble fragment is up-regulated in the biological sample, compared with the level in the control,

wherein the antigen-antibody reaction product is measured by a sandwich ELISA.

2. The method according to claim 1 , wherein the fixture is selected from the group consisting of nitrocellulose membrane, PVDF membrane (polyvinylidene difluoride membrane), 96-well plate made of polyvinyl resin or polystylene resin, and glass side glass.

3. The method according to claim 1 , wherein the secondary antibody conjugate marker is selected from the group consisting of HRP (horseradish peroxidase), alkaline phosphatase, colloid gold, FITC (poly L-lysine-fluorescein isothiocyanate), RITC (rhodamine-B-isothiocyanate), and dye.

4. The method according to claim 1 , wherein the chromogenic substrate solution is the one selected from the group consisting of TMB (3,3′,5,5′-tetramethyl bezidine), ABTS [2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)], and OPD (o-phenylenediamine).

5. The method according to claim 1 , wherein the soluble fragment is the 95 kDa ectodomain of CD93 protein released after cell culture.

6. The method according to claim 1 , wherein the soluble fragment has the amino acid sequence of SEQ ID NO:1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2011
From: PARK, YOUNG WOO; JEON, JAE WON; JUNG, JOON-GOO; CHOI, HYE IN; SOHN, MYUNG-HO; KIM, HO YOUN; CHO, MI-LA; JANG, YOUNG-SOON; MOON, JI-HUN; PARK, JI HYUN
To: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Reel/Frame 027044/0982 →
Priority Claims (2)
KR 10-2009-0006592 · Jan 28, 2009 · national
KR 10-2009-0116723 · Nov 30, 2009 · national
Continuity (1)
Related Publication 20120039911A1 · Feb 16, 2012